evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract
5831,GENE_SUMMARY,,"B2M, a tumor suppressor and regulator of the immune system, is inactivated by mutation or deletion in various cancers including non-Hodgkin's lymphoma.",,2017-10-23,,567,B2M,beta-2-microglobulin,False,ENST00000558401,NM_004048.2,IMD43,True,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5832,GENE_BACKGROUND,,"The B2M gene encodes the beta2-microglobulin (B2M) protein, a component of the human leukocyte antigen (HLA) class I molecule that is expressed by all nucleated cells. Specifically, B2M serves as the light chain of the MHC class I molecule, which functions to present peptides derived from cellular proteins to CD8+ T lymphocytes, a process critical to adaptive immune responses (PMID: 8717519). Loss-of-function B2M genomic alterations may contribute to tumor immune evasion and are prevalent in colorectal cancer and melanoma (PMID: 22833104). Additionally, serum levels of free soluble B2M are increased in many hematological and solid malignancies. Various non-immunologic context-dependent functions have been ascribed to free B2M; these include serving as a mitogenic or pro-apoptotic paracrine factor in various tumor types (PMID: 23848204, 19056512). Elevated serum B2M is a strong prognostic indicator of poor outcomes in many hematological malignancies, particularly multiple myeloma and non-Hodgkin lymphomas, although the precise mechanism underlying this correlation is not fully understood (PMID: 8507875, 15809451, 8471438).",,2017-04-26,,567,B2M,beta-2-microglobulin,False,ENST00000558401,NM_004048.2,IMD43,True,22833104,Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes.,"Cancer immunology, immunotherapy : CII",2018-09-01T20:12:00,61,9,1359-71,Bernal M et al,doi: 10.1007/s00262-012-1321-6,,0001-09-01,,15809451,International staging system for multiple myeloma.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2018-05-20T20:05:00,23,15,3412-20,Greipp PR et al,,,0001-05-20,,19056512,Beta2-microglobulin: emerging as a promising cancer therapeutic target.,0001-01-01,2018-01-01T20:09:00,14,2001-01-02,25-30,Shi C et al,doi: 10.1016/j.drudis.2008.11.001,,2001-01-02,,8507875,Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.,Blood,0001-06-15,81,12,3382-7,Greipp PR et al,,,0001-06-15,,8717519,Antigen processing and presentation by the class I major histocompatibility complex.,Annual review of immunology,1996,14,,369-96,York IA et al,,,York IA et al. Annual review of immunology. 1996;14()369-96.,,23848204,β2-Microglobulin-mediated signaling as a target for cancer therapy.,Anti-cancer agents in medicinal chemistry,2018-03-01T20:14:00,14,3,343-52,Nomura T et al,,,0001-03-01,,8471438,Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas.,British journal of cancer,0001-04-01,67,4,792-7,Johnson PW et al,,,0001-04-01,
